The 2026 "Talent-as-a-Service" Shift
In 2026, the primary driver for FSP adoption in Korea is the acute shortage of skilled clinical research professionals (CRAs, Biostatisticians, and Data Managers).
Staffing Retention Crisis: With Seoul being the world's #1 city for clinical trials, internal turnover rates at sponsors have reached nearly 25%. FSPs like ICON Strategic Solutions now offer "career-pathing" models that keep high-performing staff within the FSP ecosystem while providing continuity to the sponsor.
Embedded Expert Teams: Unlike the old "body shopping" model, 2026 FSPs provide fully trained, "ready-to-work" pods that are pre-certified in Korean Good Clinical Practice (KGCP) and specific therapeutic areas like Oncology or Rare Disease.
Hybrid Resourcing: Small and mid-sized Korean biotechs are increasingly using "Hybrid FSP" models—outsourcing 100% of data management while keeping clinical operations in-house to maintain control over site relationships.
